Great discussion all around. My hope for MedSchlr is to have discussions around emerging solutions to chronic disease. As an example, suppose a low-risk intervention on a disease. Suppose that low-risk intervention is not widely supported, for any number of reasons. Suppose one main reason: the low-risk intervention in question uses non-patented natural medicines, or pharmaceuticals with expired patents, or both, and suppose that if the intervention is found to be helpful against one or more chronic disease, that it will represent a real threat to pharma profits and reduce the need for expensive surgical procedures. Now suppose there are regular people, some with chronic diseases, who like to try stuff and read scientific developments on health topics (enter biohackers). Suppose that some of them are trying some emerging protocols already and suppose we just suggest to them a template for documenting their results as a case study. And suppose those who get on board start publishing their case studies individually. Could be on MedSchlr for discussion. The example I'm writing of is real world for me. Dr. Makis' protocol using ivermectin and fenbendazol has been reported to help cancer patients shrink their tumours. So if it's good for shrinking tumours, what about shrinking non-cancerous growths like endometriosis or fibroids? As a biohacker I tried most of this protocol (I didn't use the vitamin C or the HBOT, but did use pretty much everything else). I did it for 12 weeks. An endometrioma cyst that used to be visible by ultrasound for years on my left ovary was gone after 12 weeks of this protocol. Wrt fibroids, the results were less conclusive. Two fibroids grew and two shrank. Overall total volume of fibroids grew, but at a slower rate than recorded from prior ultrasounds. Symptoms related to the fibroids disappeared for the duration of the protocol. I would love to try another 12 weeks with more rigorous controls and documentation and publish it on MedSchlr or wherever people could access it to discuss constructively. Here's the protocol: https://isom.ca/wp-content/uploads/2024/09/Targeting-the-Mitochondrial-Stem-Cell-Connection-in-Cancer-Treatment-JOM-39.3.pdf